Citoxlab Group, a non-clinical CRO, has entered into a definitive agreement to acquire Solvo Biotechnology, a CRO specializing in drug transporter studies and the assessment of Drug-Drug Interactions (DDI). Solvo has a staff of approximately 100 people with two sites in Budapest and Szeged, Hungary. Financial terms were not disclosed.   The field of drug transporter research is growing as the investigation of the transport mechanisms becomes pivotal for drug development. Alongside metabolism d...